Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-03-11
2002-11-26
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S459000, C514S464000, C514S465000, C514S466000, C514S517000, C514S454000, C514S455000
Reexamination Certificate
active
06486198
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a methods for the treatment or prophylaxis of post-traumatic stress disorder (PTSD) using topiramate and related sulfamate derivatives and analogues, and the pharmacologically acceptable acid addition salts thereof, alone or in association with a pharmaceutically acceptable carrier.
BACKGROUND OF THE INVENTION
Chronic post-traumatic stress disorder (PTSD) is a difficult to treat condition. To date, the U.S. Food and Drug Administration has approved only one medication, sertraline, for the treatment of PTSD, and has limited the indication to women. Hypotheses on the etiology of PTSD have suggested that after exposure to traumatic events, limbic nuclei may become kindled or sensitized. Consequently, drugs known to have anti-kindling or anticonvulsant effects have been assessed as treatments for PTSD. (See Post RM et al., “Cocaine, kindling, and psychosis,”
Am J Psychiatry
133:627-634 (1976); Post RM et al., “Conditioning and sensitisation in the longitudinal course of affective illness,”
Br J Psychiatry
149:191-201 (1986); and Post RM et al., “Kindling versus quenching. Implications for the evolution and treatment of posttraumatic stress disorder,”
Ann N Y Acad Sci
821:285-295 (1997)). For example, carbamazepine may reduce reexperiencing and arousal symptoms, whereas valproate may reduce avoidance
umbing and arousal symptoms but not re-experiencing symptoms. (See Keck PE et al., “Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states and behavioural dyscontrol syndromes,”
J Clin Physchopharmacol
12(suppl 1):36-41 (1992).)
The generic class of compounds of the following formula I:
are structurally similar antiepileptic compounds that are highly effective anticonvulsants in animal tests (Maryanoff, B. E. et al.,
Med. Chem.
30:880-887 (1987); Maryanoff, B. E. et al.,
Bioorganic
&
Medicinal Chemistry Letters
3:2653-2656 (1993), McComsey, D. F. et al.,
J. Org. Chem.
1995). These compounds are covered by three U.S. Pat. Nos.: 4,5.13,006, 5,384,327 and 5,498,629. One of these compounds 2,3:4,5-bis-O-(1-methylethylidene)-&bgr;-D-fructopyranose sulfamate known as topiramate has been demonstrated in clinical trials of human epilepsy to be effective as adjunctive therapy or as monotherapy in treating simple and complex partial seizures and secondarily generalized seizures (E. Faught et. al.,
Epilepsia
36 (S4) 33, 1995; S. K. Sachdeo et al.,
Epilepsia
36 (S4) 33, 1995), and is currently marketed for the treatment of simple and complex partial seizure epilepsy with or without secondary generalized seizures in Great Britain, Finland, the United States, Sweden and elsewhere, and applications for regulatory approval are presently pending or have been approved in over 50 countries throughout the world.
Compounds of Formula I were initially found to possess anticonvulsant activity in the traditional maximal electroshock seizure (MES) test in mice (Shank, R. P. et al.,
Epilepsia
35 450-460, 1994). Subsequent studies revealed that Compounds of Formula I were also highly effective in the MES test in rats. More recently topiramate was found to effectively block seizures in several rodent models of epilepsy (J. Nakamura et al.,
Eur. J. Pharmacol.
254 83-89, 1994), and in an animal model of kindled epilepsy (A. Wauquier et al.,
Epilepsy Res.
24, 73-77, 1996).
More recently, topiramate has been shown to have efficacy in the treatment of a broad range of seizure types in adults and children. (Faught E., “Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience,”
Epilepsia
38(suppl 1):24-27 (1997); Ben-Menachem E., “Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: The European experience,”
Epilepsia
38(suppl 1):28-30 (1997); Reife R A et al., “Topiramate as adjunctive therapy in refractory partial epilepsy: Pooled analysis of data from five double-blind, placebo-controlled trials,”
Epilepsia
38(suppl 1):31-33 (1997); Rosenfeld W E et al., “Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: Retrospective study of open-label treatment,”
Epilepsia
38(suppl 1):34-36 (1997); Biton V., “Preliminary open-label experience with topiramate in primary generalized seizures,”
Epilepsia
38(suppl 1):42-44 (1997); Glauser T A, “Topiramate use in pediatric patients,”
Can J Neurol Sci
25:8-12 (1998); and Elterman R D et al., “A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topirarnate Y P Study Group.,” Neurology 52:1338-1344 (1999)). The drug has an usually broad spectrum of pharmacological properties, with several proposed mechanisms of action. In addition to carbonic anhydrase inhibition, topiramate induces state-dependent blockade of voltage-gated Na+ channels, enhances GABAergic activity at GABAA receptors, blocks glutamate inhibition at kainate/AMPA receptors, and promotes protein phosphorylation of neuronal conductance channels. Topiramate thus combines several pharmacological properties of carbamazepine and valproate. In addition, U.S. Pat. No. 5,753,693 discloses that topiramate, and the sulfamate derivatives of formula I (above) are useful for the treatment of manic-depressive bipolar disorder (MDBD).
Recent preclinical studies on topiramate have revealed previously unrecognized pharnacological properties, which suggest that topiramate should be effective in treating post traumatic stress disorder (PTSD).
SUMMARY OF THE INVENTION
In accordance with the present invention, it has been found that topiramate and related sulfamate compounds of the following formula I:
wherein X is O or CH
2
, and R
1
, R
2
, R
3
, R
4
and R
5
are as defined hereinafter, and the pharmacologically acceptable acid addition salts thereof, alone or in association with a pharmaceutically acceptable carrier, are useful in treating post traumatic stress disorder (PTSD). The compounds of the invention may also be used prophylactically to lessen the frequency and/or intensity of PTSD symptoms following a traumatic event.
This and other aspects of the invention will become apparent from the description of the invention which follows below.
REFERENCES:
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 5384327 (1995-01-01), Costanzo et al.
patent: 5498629 (1996-03-01), Costenzo et al.
Christensen O'Connor Johnson & Kindness PLLC
Krass Frederick
LandOfFree
Compounds and methods for the treatment of post traumatic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment of post traumatic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of post traumatic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2918559